280 related articles for article (PubMed ID: 26697509)
1. The Impact of Direct-Acting Antivirals in the Hepatitis C-Sustained Viral Response in Human Immunodeficiency Virus-Infected Patients With Ongoing Barriers to Care.
Cachay ER; Wyles D; Hill L; Ballard C; Torriani F; Colwell B; Kuo A; Schooley R; Mathews CW
Open Forum Infect Dis; 2015 Dec; 2(4):ofv168. PubMed ID: 26697509
[TBL] [Abstract][Full Text] [Related]
2. Present, old and future strategies for anti-HCV treatment in patients infected by genotype-1: estimation of the drug costs in the Calabria Region in the era of the directly acting antivirals.
Strazzulla A; Costa C; Pisani V; De Maria V; Giancotti F; Di Salvo S; Parisi SG; Basso M; Franzetti MM; Marascio N; Liberto MC; Barreca GS; Lamberti AG; Zicca E; Postorino MC; Matera G; Focà A; Torti C
BMC Infect Dis; 2014; 14 Suppl 5(Suppl 5):S3. PubMed ID: 25236374
[TBL] [Abstract][Full Text] [Related]
3. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
4. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
6. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.
Laguno M; Von Wichmann MA; Van den Eynde E; Navarro J; Cifuentes C; Murillas J; Veloso S; Martínez-Rebollar M; Guardiola JM; Jou A; Gómez-Sirvent JL; Cervantes M; Pineda JA; López-Calvo S; Carrero A; Montes ML; Deig E; Tapiz A; Ruiz-Mesa JD; Cruceta A; de Lazzari E; Mallolas J
Int J Infect Dis; 2016 Dec; 53():46-51. PubMed ID: 27815225
[TBL] [Abstract][Full Text] [Related]
7. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
Bruno R; Cariti G; Nasta P; Capetti A; Ravasio V; Galli M; Raise E; Palmieri G; Iannacone C; Puoti M
Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
[TBL] [Abstract][Full Text] [Related]
8. Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.
Collins LF; Chan A; Zheng J; Chow SC; Wilder JM; Muir AJ; Naggie S
Open Forum Infect Dis; 2018 Jan; 5(1):ofx264. PubMed ID: 29308413
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
10. Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Pawlotsky JM; Flisiak R; Sarin SK; Rasenack J; Piratvisuth T; Chuang WL; Peng CY; Foster GR; Shah S; Wedemeyer H; Hézode C; Zhang W; Wong KA; Li B; Avila C; Naoumov NV;
Hepatology; 2015 Oct; 62(4):1013-23. PubMed ID: 26118427
[TBL] [Abstract][Full Text] [Related]
11. A decade of hepatitis C at the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa, in the pre-direct-acting antivirals era.
Nordien R; Sonderup MW; Spearman CW
S Afr Med J; 2020 Jan; 110(2):106-111. PubMed ID: 32657679
[TBL] [Abstract][Full Text] [Related]
12. Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients.
Devaki P; Jencks D; Yee BE; Nguyen MH
Hepatol Int; 2015 Jul; 9(3):431-7. PubMed ID: 26016464
[TBL] [Abstract][Full Text] [Related]
13. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
14. Rates of Hepatocellular Carcinoma After Start of Treatment for Chronic Hepatitis C Remain High with Direct Acting Antivirals: Analysis from a Swiss Liver Transplant Center.
Karbeyaz F; Kissling S; Jaklin PJ; Bachofner J; Brunner B; Müllhaupt B; Winder T; Mertens JC; Misselwitz B; von Felten S; Siebenhüner AR
J Hepatocell Carcinoma; 2021; 8():565-574. PubMed ID: 34150679
[TBL] [Abstract][Full Text] [Related]
15. [Differential response to pegylated interferon plus ribavirin combination therapy in chronic hepatitis C and HIV/HCV co-infected patients].
Liu B; Cai WP; Hu FY; Xu M; Lan Y; Tang XP
Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):829-33. PubMed ID: 24331692
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response of patients with hepatitis C virus genotype 2 depends on pegylated interferon compliance.
Watanabe T; Konishi I; Shigematsu S; Uesugi K; Joko K; Seike H; Okada S; Miyaoka H; Nakanishi S; Abe M; Matsuura B; Michitaka K; Horiike N; Hiasa Y; Onji M
Hepatol Res; 2011 Aug; 41(8):722-30. PubMed ID: 21682826
[TBL] [Abstract][Full Text] [Related]
18. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
Manns MP; Markova AA; Calle Serrano B; Cornberg M
Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
[TBL] [Abstract][Full Text] [Related]
19. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]